Ocular Therapeutix Inc (OCUL) is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for diseases and conditions of the eye. As with any investment, it is important to perform a thorough technical analysis before making a decision. Technical indicators are commonly used tools that help investors evaluate the price performance and momentum of a stock. In the case of OCUL, several technical indicators can provide valuable insights.

The Relative Strength Index (RSI) is a popular momentum oscillator that measures the speed and change of price movements. A high RSI value suggests overbought conditions, while a low RSI value indicates oversold conditions. By monitoring the RSI of OCUL, investors can assess the stock's current momentum and potential reversal points.

Ocular Therapeutix  (OCUL) Technical Analysis

An analysis of Ocular Therapeutix Inc (OCUL) stock using technical indicators such as RSI, ADX, MACD, ROC, STOCHRSI, and WILLR. This report provides insights into the stock's performance and potential trends.

Ocular Therapeutix Inc (OCUL) Technical Analysis

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Ocular Therapeutix 

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	48.66	Neutral	64.6%
auto_graphMACD	22.36	Neutral	720.4%
auto_graphCCI	-6.54	Neutral	235.8%
auto_graphADX	20.72	Neutral	-
auto_graphATR	71.13	Buy	-
auto_graphWILLR	-70.61	Neutral	200.2%
auto_graphROC	23.29	Neutral	609.7%
auto_graphSTOCHRSI	7.18	Buy	61.3%

Buy	2	-75.00%
Hold	6	-25.00%
Sell	0	-100.00%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

Ocular Therapeutix (OCUL) Technical Analysis

Keep an eye on Ocular Therapeutix

Frequently Asked Questions

What are the technical signals for Ocular Therapeutix (OCUL) stock based on the last 30 days?

Take Your Investments to a Whole New Level